<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:e sem="disease" ids="C1568868" disease_type="Disease or Syndrome" abbrv="">Oral mucositis</z:e> (OM), a complication frequently associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> chemotherapy, may decrease treatment efficacy due to dose reduction or impair the patient's quality of life </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose was to determine the incidence and severity of OM and its sequelae in patients receiving conventional chemotherapy for various <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Two hundred twenty-seven patients (male, 33%; female, 66%) who received chemotherapy for <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e>, <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, and malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> at the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute Hospital between January 2007 and December 2008 were examined with questionnaires, prospectively </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The incidence of OM was highest in patients with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (76.5%), then <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e> (67.7%), <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (63%), <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> (57.8%), and malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (42.9%) </plain></SENT>
<SENT sid="4" pm="."><plain>However, patients who experienced severe OM (â‰¥grade 3) were rare: at most 4.8% </plain></SENT>
<SENT sid="5" pm="."><plain>The high-risk regimens for OM were TPF (85.7%), FOLFIRI (80%), CAF (78.8%), AC (70.6%), and FOLFOX (60%) </plain></SENT>
<SENT sid="6" pm="."><plain>OM was associated with gastrointestinal adverse events, <z:hpo ids='HP_0002039'>anorexia</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, and <z:hpo ids='HP_0002015'>dysphagia</z:hpo>, which aggravated quality of life </plain></SENT>
<SENT sid="7" pm="."><plain>There was no correlation between incidence of OM and prior therapy, PS, oral care, or laboratory data </plain></SENT>
<SENT sid="8" pm="."><plain>There was no statistically significant correlation between OM and overall survival </plain></SENT>
<SENT sid="9" pm="."><plain>The predictive factor was history of OM in previous chemotherapy </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: OM frequently occurs in patients with various <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> receiving conventional chemotherapy </plain></SENT>
<SENT sid="11" pm="."><plain>Despite low-grade OM, they might cause gastrointestinal adverse events </plain></SENT>
<SENT sid="12" pm="."><plain>Adequate preventive treatment for OM is required depending on each chemotherapy regimen and each patient's OM history </plain></SENT>
</text></document>